These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 19451574)

  • 1. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
    de Groot K; Harper L; Jayne DR; Flores Suarez LF; Gregorini G; Gross WL; Luqmani R; Pusey CD; Rasmussen N; Sinico RA; Tesar V; Vanhille P; Westman K; Savage CO;
    Ann Intern Med; 2009 May; 150(10):670-80. PubMed ID: 19451574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis (CYCLOPS study)].
    Kötter I
    Z Rheumatol; 2009 Sep; 68(7):575-7. PubMed ID: 19652987
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-term data from the CYCLOPS study].
    Haubitz M
    Z Rheumatol; 2013 May; 72(4):402-3. PubMed ID: 23552980
    [No Abstract]   [Full Text] [Related]  

  • 4. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
    Harper L; Morgan MD; Walsh M; Hoglund P; Westman K; Flossmann O; Tesar V; Vanhille P; de Groot K; Luqmani R; Flores-Suarez LF; Watts R; Pusey C; Bruchfeld A; Rasmussen N; Blockmans D; Savage CO; Jayne D;
    Ann Rheum Dis; 2012 Jun; 71(6):955-60. PubMed ID: 22128076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
    Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience.
    Rihová Z; Jancová E; Merta M; Zabka J; Rysavá R; Bartůnková J; Kolárova I; Tesar V
    Prague Med Rep; 2004; 105(1):64-8. PubMed ID: 15354947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.
    Haubitz M; Schellong S; Göbel U; Schurek HJ; Schaumann D; Koch KM; Brunkhorst R
    Arthritis Rheum; 1998 Oct; 41(10):1835-44. PubMed ID: 9778225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
    Levine SM
    Ann Intern Med; 2010 Jan; 152(1):65; author reply 65. PubMed ID: 20048281
    [No Abstract]   [Full Text] [Related]  

  • 9. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.
    de Groot K; Adu D; Savage CO;
    Nephrol Dial Transplant; 2001 Oct; 16(10):2018-27. PubMed ID: 11572891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
    Jayne D; Rasmussen N; Andrassy K; Bacon P; Tervaert JW; Dadoniené J; Ekstrand A; Gaskin G; Gregorini G; de Groot K; Gross W; Hagen EC; Mirapeix E; Pettersson E; Siegert C; Sinico A; Tesar V; Westman K; Pusey C;
    N Engl J Med; 2003 Jul; 349(1):36-44. PubMed ID: 12840090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
    Hebert LA; Rovin BH
    Ann Intern Med; 2010 Jan; 152(1):64; author reply 65. PubMed ID: 20048278
    [No Abstract]   [Full Text] [Related]  

  • 12. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
    Hu W; Liu C; Xie H; Chen H; Liu Z; Li L
    Nephrol Dial Transplant; 2008 Apr; 23(4):1307-12. PubMed ID: 18065810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
    Padhan P
    Ann Intern Med; 2010 Jan; 152(1):64; author reply 65. PubMed ID: 20048279
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with seven Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with remission-induction therapy with intravenous cyclophosphamide according to the CYCLOPS protocol.
    Oiwa H; Yamasaki S; Endo K; Nojima T; Kumagai K; Sugiyama E
    Intern Med; 2014; 53(20):2291-6. PubMed ID: 25318790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
    Karras A; Pagnoux C; Haubitz M; Groot K; Puechal X; Tervaert JWC; Segelmark M; Guillevin L; Jayne D;
    Ann Rheum Dis; 2017 Oct; 76(10):1662-1668. PubMed ID: 28546260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
    Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
    Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.